{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T08:30:52Z","timestamp":1774945852517,"version":"3.50.1"},"publisher-location":"Singapore","reference-count":217,"publisher":"Springer Nature Singapore","isbn-type":[{"value":"9789811903939","type":"print"},{"value":"9789811903946","type":"electronic"}],"license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022]]},"DOI":"10.1007\/978-981-19-0394-6_13","type":"book-chapter","created":{"date-parts":[[2022,5,3]],"date-time":"2022-05-03T14:05:39Z","timestamp":1651586739000},"page":"189-213","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Rare Diseases in Glycosphingolipid Metabolism"],"prefix":"10.1007","author":[{"given":"Hongwen","family":"Zhou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhoulu","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yiwen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qinyi","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Moran","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuai","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Baowen","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingya","family":"Ye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wanzi","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhenzhen","family":"Fu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yingyun","family":"Gong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,5,3]]},"reference":[{"key":"13_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3233\/TRD-160005","volume":"2","author":"CR Ferreira","year":"2017","unstructured":"Ferreira, C. R., & Gahl, W. A. (2017). Lysosomal storage diseases. Translational Science of Rare Diseases, 2, 1\u201371.","journal-title":"Translational Science of Rare Diseases"},{"key":"13_CR2","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1016\/j.bbadis.2011.03.018","volume":"1812","author":"A Caciotti","year":"2011","unstructured":"Caciotti, A., et al. (2011). GM1 gangliosidosis and Morquio B disease: An update on genetic alterations and clinical findings. Biochimica et Biophysica Acta, 1812, 782\u2013790.","journal-title":"Biochimica et Biophysica Acta"},{"key":"13_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00439-013-1358-4","volume":"133","author":"PD Stenson","year":"2014","unstructured":"Stenson, P. D., et al. (2014). The human gene mutation database: Building a comprehensive mutation repository for clinical and molecular genetics, diagnostic testing and personalized genomic medicine. Human Genetics, 133, 1\u20139.","journal-title":"Human Genetics"},{"key":"13_CR4","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.ymgme.2005.12.009","volume":"88","author":"I Sinigerska","year":"2006","unstructured":"Sinigerska, I., et al. (2006). Founder mutation causing infantile GM1-gangliosidosis in the gypsy population. Molecular Genetics and Metabolism, 88, 93\u201395.","journal-title":"Molecular Genetics and Metabolism"},{"key":"13_CR5","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1007\/s004310050685","volume":"156","author":"JC Coelho","year":"1997","unstructured":"Coelho, J. C., Wajner, M., Burin, M. G., Vargas, C. R., & Giugliani, R. (1997). Selective screening of 10,000 high-risk Brazilian patients for the detection of inborn errors of metabolism. European Journal of Pediatrics, 156, 650\u2013654.","journal-title":"European Journal of Pediatrics"},{"key":"13_CR6","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1034\/j.1399-0004.1999.560215.x","volume":"56","author":"MH Severini","year":"1999","unstructured":"Severini, M. H., Silva, C. D., Sopelsa, A., Coelho, J. C., & Giugliani, R. (1999). High frequency of type 1 GM1 gangliosidosis in southern Brazil. Clinical Genetics, 56, 168\u2013169.","journal-title":"Clinical Genetics"},{"key":"13_CR7","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1023\/A:1005303332529","volume":"20","author":"HM Lenicker","year":"1997","unstructured":"Lenicker, H. M., Vassallo Agius, P., Young, E. P., & Attard Montalto, S. P. (1997). Infantile generalized GM1 gangliosidosis: High incidence in the Maltese Islands. Journal of Inherited Metabolic Disease, 20, 723\u2013724.","journal-title":"Journal of Inherited Metabolic Disease"},{"key":"13_CR8","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1089\/gte.2005.9.126","volume":"9","author":"T Georgiou","year":"2005","unstructured":"Georgiou, T., et al. (2005). The Arg482His mutation in the beta-galactosidase gene is responsible for a high frequency of GM1 gangliosidosis carriers in a Cypriot village. Genetic Testing, 9, 126\u2013132.","journal-title":"Genetic Testing"},{"key":"13_CR9","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1002\/ajmg.a.37468","volume":"170","author":"DS Regier","year":"2016","unstructured":"Regier, D. S., et al. (2016). MRI\/MRS as a surrogate marker for clinical progression in GM1 Gangliosidosis. American Journal of Medical Genetics. Part A, 170, 634\u2013644.","journal-title":"American Journal of Medical Genetics. Part A"},{"key":"13_CR10","first-page":"260","volume":"33","author":"ST Alniemi","year":"2018","unstructured":"Alniemi, S. T., Amin, S. R., Sculley, L., & Bakri, S. J. (2018). Ultrasound biomicroscopy in pseudophakic patients with unexplained recurrent hyphema or vitreous hemorrhage. Seminars in Ophthalmology, 33, 260\u2013264.","journal-title":"Seminars in Ophthalmology"},{"key":"13_CR11","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1002\/(SICI)1098-1004(200004)15:4<354::AID-HUMU8>3.0.CO;2-L","volume":"15","author":"A Morrone","year":"2000","unstructured":"Morrone, A., et al. (2000). Beta-galactosidase gene mutations affecting the lysosomal enzyme and the elastin-binding protein in GM1-gangliosidosis patients with cardiac involvement. Human Mutation, 15, 354\u2013366.","journal-title":"Human Mutation"},{"key":"13_CR12","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/S1096-7192(02)00199-3","volume":"78","author":"T Okumiya","year":"2003","unstructured":"Okumiya, T., Sakuraba, H., Kase, R., & Sugiura, T. (2003). Imbalanced substrate specificity of mutant beta-galactosidase in patients with Morquio B disease. Molecular Genetics and Metabolism, 78, 51\u201358.","journal-title":"Molecular Genetics and Metabolism"},{"key":"13_CR13","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1016\/j.ymthe.2017.01.009","volume":"25","author":"HL Gray-Edwards","year":"2017","unstructured":"Gray-Edwards, H. L., et al. (2017). Novel biomarkers of human GM1 Gangliosidosis reflect the clinical efficacy of gene therapy in a feline model. Molecular Therapy, 25, 892\u2013903.","journal-title":"Molecular Therapy"},{"key":"13_CR14","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.brainres.2006.11.039","volume":"1133","author":"H Satoh","year":"2007","unstructured":"Satoh, H., et al. (2007). Cerebrospinal fluid biomarkers showing neurodegeneration in dogs with GM1 gangliosidosis: Possible use for assessment of a therapeutic regimen. Brain Research, 1133, 200\u2013208.","journal-title":"Brain Research"},{"key":"13_CR15","first-page":"518","volume":"50","author":"N Parakh","year":"2002","unstructured":"Parakh, N., Gupta, H. L., & Jain, A. (2002). Evaluation of enzymes in serum and cerebrospinal fluid in cases of stroke. Neurology India, 50, 518\u2013519.","journal-title":"Neurology India"},{"key":"13_CR16","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/0379-0738(92)90107-8","volume":"52","author":"E Osuna","year":"1992","unstructured":"Osuna, E., Perez-Carceles, M. D., Luna, A., & Pounder, D. J. (1992). Efficacy of cerebro-spinal fluid biochemistry in the diagnosis of brain insult. Forensic Science International, 52, 193\u2013198.","journal-title":"Forensic Science International"},{"key":"13_CR17","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.jpeds.2019.08.016","volume":"215","author":"L Arash-Kaps","year":"2019","unstructured":"Arash-Kaps, L., et al. (2019). The clinical and molecular spectrum of GM1 gangliosidosis. The Journal of Pediatrics, 215, 152\u2013157e153.","journal-title":"The Journal of Pediatrics"},{"key":"13_CR18","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1177\/104063870401600308","volume":"16","author":"H Satoh","year":"2004","unstructured":"Satoh, H., Yamato, O., Asano, T., Yamasaki, M., & Maede, Y. (2004). Increased concentration of GM1-ganglioside in cerebrospinal fluid in dogs with GM1- and GM2-gangliosidoses and its clinical application for diagnosis. Journal of Veterinary Diagnostic Investigation, 16, 223\u2013226.","journal-title":"Journal of Veterinary Diagnostic Investigation"},{"key":"13_CR19","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1177\/0883073807307088","volume":"23","author":"N Brunetti-Pierri","year":"2008","unstructured":"Brunetti-Pierri, N., et al. (2008). Brain proton magnetic resonance spectroscopy and neuromuscular pathology in a patient with GM1 gangliosidosis. Journal of Child Neurology, 23, 73\u201378.","journal-title":"Journal of Child Neurology"},{"key":"13_CR20","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1093\/brain\/awg089","volume":"126","author":"M Jeyakumar","year":"2003","unstructured":"Jeyakumar, M., et al. (2003). Central nervous system inflammation is a hallmark of pathogenesis in mouse models of GM1 and GM2 gangliosidosis. Brain, 126, 974\u2013987.","journal-title":"Brain"},{"key":"13_CR21","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.ymgme.2008.04.012","volume":"94","author":"N Brunetti-Pierri","year":"2008","unstructured":"Brunetti-Pierri, N., & Scaglia, F. (2008). GM1 gangliosidosis: Review of clinical, molecular, and therapeutic aspects. Molecular Genetics and Metabolism, 94, 391\u2013396.","journal-title":"Molecular Genetics and Metabolism"},{"key":"13_CR22","doi-asserted-by":"publisher","first-page":"6881","DOI":"10.3390\/ijms21186881","volume":"21","author":"AE Ryckman","year":"2020","unstructured":"Ryckman, A. E., Brockhausen, I., & Walia, J. S. (2020). Metabolism of glycosphingolipids and their role in the pathophysiology of lysosomal storage disorders. International Journal of Molecular Sciences, 21, 6881.","journal-title":"International Journal of Molecular Sciences"},{"key":"13_CR23","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.ymgme.2017.04.011","volume":"121","author":"JRJ Utz","year":"2017","unstructured":"Utz, J. R. J., et al. (2017). Infantile gangliosidoses: Mapping a timeline of clinical changes. Molecular Genetics and Metabolism, 121, 170\u2013179.","journal-title":"Molecular Genetics and Metabolism"},{"key":"13_CR24","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s12881-017-0417-4","volume":"18","author":"P Karimzadeh","year":"2017","unstructured":"Karimzadeh, P., et al. (2017). Case reports of juvenile GM1 gangliosidosisis type II caused by mutation in GLB1 gene. BMC Medical Genetics, 18, 73.","journal-title":"BMC Medical Genetics"},{"key":"13_CR25","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/1423-0127-17-79","volume":"17","author":"CF Yang","year":"2010","unstructured":"Yang, C. F., Wu, J. Y., & Tsai, F. J. (2010). Three novel beta-galactosidase gene mutations in Han Chinese patients with GM1 gangliosidosis are correlated with disease severity. Journal of Biomedical Science, 17, 79.","journal-title":"Journal of Biomedical Science"},{"key":"13_CR26","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/0006-291X(78)90915-4","volume":"82","author":"DA Wenger","year":"1978","unstructured":"Wenger, D. A., Tarby, T. J., & Wharton, C. (1978). Macular cherry-red spots and myoclonus with dementia: Coexistent neuraminidase and beta-galactosidase deficiencies. Biochemical and Biophysical Research Communications, 82, 589\u2013595.","journal-title":"Biochemical and Biophysical Research Communications"},{"key":"13_CR27","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1016\/S0092-8674(88)90999-3","volume":"54","author":"NJ Galjart","year":"1988","unstructured":"Galjart, N. J., et al. (1988). Expression of cDNA encoding the human \u201cprotective protein\u201d associated with lysosomal beta-galactosidase and neuraminidase: Homology to yeast proteases. Cell, 54, 755\u2013764.","journal-title":"Cell"},{"key":"13_CR28","doi-asserted-by":"publisher","first-page":"4535","DOI":"10.1073\/pnas.79.15.4535","volume":"79","author":"A D\u2019Azzo","year":"1982","unstructured":"D\u2019Azzo, A., Hoogeveen, A., Reuser, A. J., Robinson, D., & Galjaard, H. (1982). Molecular defect in combined beta-galactosidase and neuraminidase deficiency in man. Proceedings of the National Academy of Sciences of the United States of America, 79, 4535\u20134539.","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"13_CR29","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1212\/WNL.0b013e31825f047a","volume":"79","author":"TM Pierson","year":"2012","unstructured":"Pierson, T. M., et al. (2012). Exome sequencing as a diagnostic tool in a case of undiagnosed juvenile-onset GM1-gangliosidosis. Neurology, 79, 123\u2013126.","journal-title":"Neurology"},{"key":"13_CR30","doi-asserted-by":"publisher","first-page":"209","DOI":"10.2147\/TACG.S206076","volume":"14","author":"AK Rha","year":"2021","unstructured":"Rha, A. K., Maguire, A. S., & Martin, D. R. (2021). GM1 Gangliosidosis: Mechanisms and management. The Application of Clinical Genetics, 14, 209\u2013233.","journal-title":"The Application of Clinical Genetics"},{"key":"13_CR31","doi-asserted-by":"publisher","first-page":"231ra248","DOI":"10.1126\/scitranslmed.3007733","volume":"6","author":"VJ McCurdy","year":"2014","unstructured":"McCurdy, V. J., et al. (2014). Sustained normalization of neurological disease after intracranial gene therapy in a feline model. Science Translational Medicine, 6, 231ra248.","journal-title":"Science Translational Medicine"},{"key":"13_CR32","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1016\/j.braindev.2008.11.004","volume":"31","author":"T Sawada","year":"2009","unstructured":"Sawada, T., et al. (2009). Intracerebral cell transplantation therapy for murine GM1 gangliosidosis. Brain Dev, 31, 717\u2013724.","journal-title":"Brain Dev"},{"key":"13_CR33","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.ymgme.2015.12.002","volume":"117","author":"J Condori","year":"2016","unstructured":"Condori, J., et al. (2016). Enzyme replacement for GM1-gangliosidosis: Uptake, lysosomal activation, and cellular disease correction using a novel beta-galactosidase:RTB lectin fusion. Molecular Genetics and Metabolism, 117, 199\u2013209.","journal-title":"Molecular Genetics and Metabolism"},{"key":"13_CR34","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.ejmech.2016.09.095","volume":"126","author":"S Front","year":"2017","unstructured":"Front, S., et al. (2017). (5aR)-5a-C-Pentyl-4-epi-isofagomine: A powerful inhibitor of lysosomal beta-galactosidase and a remarkable chaperone for mutations associated with GM1-gangliosidosis and Morquio disease type B. European Journal of Medicinal Chemistry, 126, 160\u2013170.","journal-title":"European Journal of Medicinal Chemistry"},{"key":"13_CR35","doi-asserted-by":"publisher","first-page":"100513","DOI":"10.1016\/j.ymgmr.2019.100513","volume":"21","author":"YL Latour","year":"2019","unstructured":"Latour, Y. L., et al. (2019). Human GLB1 knockout cerebral organoids: A model system for testing AAV9-mediated GLB1 gene therapy for reducing GM1 ganglioside storage in GM1 gangliosidosis. Molecular Genetics and Metabolism Reports, 21, 100513.","journal-title":"Molecular Genetics and Metabolism Reports"},{"key":"13_CR36","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1007\/s00439-020-02153-3","volume":"139","author":"FE Mohamed","year":"2020","unstructured":"Mohamed, F. E., et al. (2020). The pharmacological chaperone N-n-butyl-deoxygalactonojirimycin enhances \u03b2-galactosidase processing and activity in fibroblasts of a patient with infantile GM1-gangliosidosis. Human Genetics, 139, 657\u2013673.","journal-title":"Human Genetics"},{"key":"13_CR37","doi-asserted-by":"publisher","first-page":"6388","DOI":"10.1073\/pnas.96.11.6388","volume":"96","author":"M Jeyakumar","year":"1999","unstructured":"Jeyakumar, M., et al. (1999). Delayed symptom onset and increased life expectancy in Sandhoff disease mice treated with N-butyldeoxynojirimycin. Proceedings of the National Academy of Sciences of the United States of America, 96, 6388\u20136393.","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"13_CR38","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1172\/JCI2127","volume":"101","author":"F Norflus","year":"1998","unstructured":"Norflus, F., et al. (1998). Bone marrow transplantation prolongs life span and ameliorates neurologic manifestations in Sandhoff disease mice. The Journal of Clinical Investigation, 101, 1881\u20131888.","journal-title":"The Journal of Clinical Investigation"},{"key":"13_CR39","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1093\/hmg\/11.11.1343","volume":"11","author":"R Myerowitz","year":"2002","unstructured":"Myerowitz, R., et al. (2002). Molecular pathophysiology in Tay-Sachs and Sandhoff diseases as revealed by gene expression profiling. Human Molecular Genetics, 11, 1343\u20131350.","journal-title":"Human Molecular Genetics"},{"key":"13_CR40","doi-asserted-by":"publisher","first-page":"6213","DOI":"10.3390\/ijms21176213","volume":"21","author":"AF Leal","year":"2020","unstructured":"Leal, A. F., et al. (2020). GM2 Gangliosidoses: Clinical features, pathophysiological aspects, and current therapies. International Journal of Molecular Sciences, 21, 6213.","journal-title":"International Journal of Molecular Sciences"},{"key":"13_CR41","doi-asserted-by":"publisher","first-page":"68","DOI":"10.2174\/1566523218666180404162622","volume":"18","author":"MB Cachon-Gonzalez","year":"2018","unstructured":"Cachon-Gonzalez, M. B., Zaccariotto, E., & Cox, T. M. (2018). Genetics and therapies for GM2 Gangliosidosis. Current Gene Therapy, 18, 68\u201389.","journal-title":"Current Gene Therapy"},{"key":"13_CR42","doi-asserted-by":"publisher","first-page":"10195","DOI":"10.1523\/JNEUROSCI.0822-13.2013","volume":"33","author":"K Sandhoff","year":"2013","unstructured":"Sandhoff, K., & Harzer, K. (2013). Gangliosides and gangliosidoses: Principles of molecular and metabolic pathogenesis. The Journal of Neuroscience, 33, 10195\u201310208.","journal-title":"The Journal of Neuroscience"},{"key":"13_CR43","doi-asserted-by":"publisher","first-page":"2566","DOI":"10.3390\/ijms21072566","volume":"21","author":"B Breiden","year":"2020","unstructured":"Breiden, B., & Sandhoff, K. (2020). Mechanism of secondary ganglioside and lipid accumulation in lysosomal disease. International Journal of Molecular Sciences, 21, 2566.","journal-title":"International Journal of Molecular Sciences"},{"key":"13_CR44","doi-asserted-by":"publisher","first-page":"17.16.11","DOI":"10.1002\/0471142905.hg1716s83","volume":"83","author":"P Hall","year":"2014","unstructured":"Hall, P., Minnich, S., Teigen, C., & Raymond, K. (2014). Diagnosing lysosomal storage disorders: The GM2 Gangliosidoses. Current Protocols in Human Genetics, 83, 17.16.11\u201317.16.18.","journal-title":"Current Protocols in Human Genetics"},{"key":"13_CR45","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.gene.2012.06.080","volume":"506","author":"L Gort","year":"2012","unstructured":"Gort, L., de Olano, N., Macias-Vidal, J., Coll, M. A., & Spanish, G. M. W. G. (2012). GM2 gangliosidoses in Spain: Analysis of the HEXA and HEXB genes in 34 Tay-Sachs and 14 Sandhoff patients. Gene, 506, 25\u201330.","journal-title":"Gene"},{"key":"13_CR46","doi-asserted-by":"publisher","first-page":"e3205","DOI":"10.1002\/jgm.3205","volume":"22","author":"J Beegle","year":"2020","unstructured":"Beegle, J., Hendrix, K., Maciel, H., Nolta, J. A., & Anderson, J. S. (2020). Improvement of motor and behavioral activity in Sandhoff mice transplanted with human CD34+ cells transduced with a HexA\/HexB expressing lentiviral vector. The Journal of Gene Medicine, 22, e3205.","journal-title":"The Journal of Gene Medicine"},{"key":"13_CR47","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/S2352-4642(17)30087-1","volume":"2","author":"R Giugliani","year":"2018","unstructured":"Giugliani, R., et al. (2018). Neurological manifestations of lysosomal disorders and emerging therapies targeting the CNS. The Lancet Child & Adolescent Health, 2, 56\u201368.","journal-title":"The Lancet Child & Adolescent Health"},{"key":"13_CR48","doi-asserted-by":"publisher","first-page":"9150","DOI":"10.1074\/jbc.M609304200","volume":"282","author":"GH Maegawa","year":"2007","unstructured":"Maegawa, G. H., et al. (2007). Pyrimethamine as a potential pharmacological chaperone for late-onset forms of GM2 gangliosidosis. The Journal of Biological Chemistry, 282, 9150\u20139161.","journal-title":"The Journal of Biological Chemistry"},{"key":"13_CR49","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1021\/jm101443u","volume":"54","author":"KS Bateman","year":"2011","unstructured":"Bateman, K. S., Cherney, M. M., Mahuran, D. J., Tropak, M., & James, M. N. (2011). Crystal structure of beta-hexosaminidase B in complex with pyrimethamine, a potential pharmacological chaperone. Journal of Medicinal Chemistry, 54, 1421\u20131429.","journal-title":"Journal of Medicinal Chemistry"},{"key":"13_CR50","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.ymgme.2010.09.004","volume":"102","author":"JT Clarke","year":"2011","unstructured":"Clarke, J. T., et al. (2011). An open-label phase I\/II clinical trial of pyrimethamine for the treatment of patients affected with chronic GM2 gangliosidosis (Tay-Sachs or Sandhoff variants). Molecular Genetics and Metabolism, 102, 6\u201312.","journal-title":"Molecular Genetics and Metabolism"},{"key":"13_CR51","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s13023-015-0260-7","volume":"10","author":"E Osher","year":"2015","unstructured":"Osher, E., et al. (2015). Effect of cyclic, low dose pyrimethamine treatment in patients with late onset Tay Sachs: An open label, extended pilot study. Orphanet Journal of Rare Diseases, 10, 45.","journal-title":"Orphanet Journal of Rare Diseases"},{"key":"13_CR52","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1007\/s11064-013-0992-5","volume":"38","author":"JR Arthur","year":"2013","unstructured":"Arthur, J. R., et al. (2013). Ethylenedioxy-PIP2 oxalate reduces ganglioside storage in juvenile Sandhoff disease mice. Neurochemical Research, 38, 866\u2013875.","journal-title":"Neurochemical Research"},{"key":"13_CR53","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.omtm.2018.10.011","volume":"12","author":"E Woodley","year":"2019","unstructured":"Woodley, E., et al. (2019). Efficacy of a Bicistronic vector for correction of Sandhoff disease in a mouse model. Molecular Therapy\u2014Methods & Clinical Development, 12, 47\u201357.","journal-title":"Molecular Therapy\u2014Methods & Clinical Development"},{"key":"13_CR54","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1038\/s41434-019-0120-5","volume":"27","author":"L Ou","year":"2020","unstructured":"Ou, L., et al. (2020). A novel gene editing system to treat both Tay-Sachs and Sandhoff diseases. Gene Therapy, 27, 226\u2013236.","journal-title":"Gene Therapy"},{"key":"13_CR55","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.pharmthera.2009.01.003","volume":"122","author":"R Schiffmann","year":"2009","unstructured":"Schiffmann, R. (2009). Fabry disease. Pharmacology & Therapeutics, 122, 65\u201377.","journal-title":"Pharmacology & Therapeutics"},{"key":"13_CR56","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/BF01986897","volume":"43","author":"J Fabry","year":"1898","unstructured":"Fabry, J. (1898). Ein Beitrag zur Kenntniss der Purpura haemorrhagica nodularis (Purpura papulosa haemorrhagica Hebrae). Archiv f\u00fcr Dermatologie und Syphilis, 43, 187\u2013200.","journal-title":"Archiv f\u00fcr Dermatologie und Syphilis"},{"key":"13_CR57","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1111\/j.1365-2133.1898.tb16317.x","volume":"10","author":"W Anderson","year":"1898","unstructured":"Anderson, W. (1898). A case of \u201cAngeio-Keratoma\u201d*. British Journal of Dermatology, 10, 113\u2013117.","journal-title":"British Journal of Dermatology"},{"key":"13_CR58","unstructured":"International Fabry Disease Genotype-Phenotype Database (dbFGP). Retrieved from http:\/\/www.dbfgp.org\/dbFgp\/fabry\/FabryGP.html."},{"key":"13_CR59","doi-asserted-by":"publisher","first-page":"122","DOI":"10.3390\/medicina55050122","volume":"55","author":"A \u010cerkauskait\u0117","year":"2019","unstructured":"\u010cerkauskait\u0117, A., et al. (2019). Genotype-phenotype correlation in a new Fabry-disease-causing mutation. Medicina (Kaunas, Lithuania), 55, 122.","journal-title":"Medicina (Kaunas, Lithuania)"},{"key":"13_CR60","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1111\/cge.12449","volume":"88","author":"BE Smid","year":"2015","unstructured":"Smid, B. E., et al. (2015). Diagnostic dilemmas in Fabry disease: A case series study on GLA mutations of unknown clinical significance. Clinical Genetics, 88, 161\u2013166.","journal-title":"Clinical Genetics"},{"key":"13_CR61","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1001\/jama.281.3.249","volume":"281","author":"PJ Meikle","year":"1999","unstructured":"Meikle, P. J., Hopwood, J. J., Clague, A. E., & Carey, W. F. (1999). Prevalence of lysosomal storage disorders. The Journal of the American Medical Association, 281, 249\u2013254.","journal-title":"The Journal of the American Medical Association"},{"key":"13_CR62","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.jpeds.2014.09.023","volume":"166","author":"PV Hopkins","year":"2015","unstructured":"Hopkins, P. V., et al. (2015). Lysosomal storage disorder screening implementation: Findings from the first six months of full population pilot testing in Missouri. The Journal of Pediatrics, 166, 172\u2013177.","journal-title":"The Journal of Pediatrics"},{"key":"13_CR63","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1007\/s00431-017-2950-8","volume":"176","author":"C Colon","year":"2017","unstructured":"Colon, C., et al. (2017). Newborn screening for Fabry disease in the north-west of Spain. European Journal of Pediatrics, 176, 1075\u20131081.","journal-title":"European Journal of Pediatrics"},{"key":"13_CR64","doi-asserted-by":"publisher","first-page":"24","DOI":"10.3390\/ijns5020024","volume":"5","author":"AB Burlina","year":"2019","unstructured":"Burlina, A. B., et al. (2019). Implementation of second-tier tests in newborn screening for lysosomal disorders in north eastern Italy. International Journal of Neonatal Screening, 5, 24.","journal-title":"International Journal of Neonatal Screening"},{"key":"13_CR65","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1161\/CIRCGENETICS.109.862920","volume":"2","author":"HY Lin","year":"2009","unstructured":"Lin, H. Y., et al. (2009). High incidence of the cardiac variant of Fabry disease revealed by newborn screening in the Taiwan Chinese population. Circulation. Cardiovascular Genetics, 2, 450\u2013456.","journal-title":"Circulation. Cardiovascular Genetics"},{"key":"13_CR66","first-page":"1186","volume":"53","author":"CM Eng","year":"1993","unstructured":"Eng, C. M., Resnick-Silverman, L. A., Niehaus, D. J., Astrin, K. H., & Desnick, R. J. (1993). Nature and frequency of mutations in the alpha-galactosidase a gene that cause Fabry disease. American Journal of Human Genetics, 53, 1186\u20131197.","journal-title":"American Journal of Human Genetics"},{"key":"13_CR67","doi-asserted-by":"publisher","first-page":"129437","DOI":"10.1016\/j.bbagen.2019.129437","volume":"1864","author":"JJ Miller","year":"2020","unstructured":"Miller, J. J., Kanack, A. J., & Dahms, N. M. (2020). Progress in the understanding and treatment of Fabry disease. Biochimica et Biophysica Acta - General Subjects, 1864, 129437.","journal-title":"Biochimica et Biophysica Acta - General Subjects"},{"key":"13_CR68","volume-title":"Fabry disease: Perspectives from 5 years of FOS","author":"M Beck","year":"2006","unstructured":"Beck, M. (2006). In A. Mehta, M. Beck, & G. Sunder-Plassmann (Eds.), Fabry disease: Perspectives from 5 years of FOS. Oxford PharmaGenesis."},{"key":"13_CR69","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/s41572-018-0025-4","volume":"4","author":"FM Platt","year":"2018","unstructured":"Platt, F. M., d'Azzo, A., Davidson, B. L., Neufeld, E. F., & Tifft, C. J. (2018). Lysosomal storage diseases. Nature Reviews. Disease Primers, 4, 27.","journal-title":"Nature Reviews. Disease Primers"},{"key":"13_CR70","doi-asserted-by":"publisher","first-page":"425","DOI":"10.7326\/0003-4819-146-6-200703200-00007","volume":"146","author":"JT Clarke","year":"2007","unstructured":"Clarke, J. T. (2007). Narrative review: Fabry disease. Annals of Internal Medicine, 146, 425\u2013433.","journal-title":"Annals of Internal Medicine"},{"key":"13_CR71","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/j.ijcard.2014.09.001","volume":"177","author":"BE Smid","year":"2014","unstructured":"Smid, B. E., et al. (2014). Uncertain diagnosis of Fabry disease: Consensus recommendation on diagnosis in adults with left ventricular hypertrophy and genetic variants of unknown significance. International Journal of Cardiology, 177, 400\u2013408.","journal-title":"International Journal of Cardiology"},{"key":"13_CR72","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s13023-015-0253-6","volume":"10","author":"M Biegstraaten","year":"2015","unstructured":"Biegstraaten, M., et al. (2015). Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: The European Fabry working group consensus document. Orphanet Journal of Rare Diseases, 10, 36.","journal-title":"Orphanet Journal of Rare Diseases"},{"key":"13_CR73","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.cca.2017.01.014","volume":"466","author":"M Mirzaian","year":"2017","unstructured":"Mirzaian, M., et al. (2017). Simultaneous quantitation of sphingoid bases by UPLC-ESI-MS\/MS with identical (13)C-encoded internal standards. Clinica Chimica Acta, 466, 178\u2013184.","journal-title":"Clinica Chimica Acta"},{"key":"13_CR74","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1136\/postgradmedj-2018-136056","volume":"94","author":"T Cairns","year":"2018","unstructured":"Cairns, T., et al. (2018). Hot topics in Fabry disease. Postgraduate Medical Journal, 94, 709\u2013713.","journal-title":"Postgraduate Medical Journal"},{"key":"13_CR75","doi-asserted-by":"publisher","first-page":"8080","DOI":"10.3390\/ijms21218080","volume":"21","author":"I Simonetta","year":"2020","unstructured":"Simonetta, I., Tuttolomondo, A., Daidone, M., & Pinto, A. (2020). Biomarkers in Anderson-Fabry disease. International Journal of Molecular Sciences, 21, 8080.","journal-title":"International Journal of Molecular Sciences"},{"key":"13_CR76","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1136\/jmg.38.11.769","volume":"38","author":"KD MacDermot","year":"2001","unstructured":"MacDermot, K. D., Holmes, A., & Miners, A. H. (2001). Anderson-Fabry disease: Clinical manifestations and impact of disease in a cohort of 60 obligate carrier females. Journal of Medical Genetics, 38, 769\u2013775.","journal-title":"Journal of Medical Genetics"},{"key":"13_CR77","doi-asserted-by":"publisher","first-page":"551","DOI":"10.2147\/TCRM.S247814","volume":"16","author":"I Vardarli","year":"2020","unstructured":"Vardarli, I., Rischpler, C., Herrmann, K., & Weidemann, F. (2020). Diagnosis and screening of patients with Fabry disease. Therapeutics and Clinical Risk Management, 16, 551\u2013558.","journal-title":"Therapeutics and Clinical Risk Management"},{"key":"13_CR78","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJM200107053450102","volume":"345","author":"CM Eng","year":"2001","unstructured":"Eng, C. M., et al. (2001). Safety and efficacy of recombinant human alpha-galactosidase a replacement therapy in Fabry\u2019s disease. The New England Journal of Medicine, 345, 9\u201316.","journal-title":"The New England Journal of Medicine"},{"key":"13_CR79","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1681\/ASN.2014121226","volume":"27","author":"M Lenders","year":"2016","unstructured":"Lenders, M., et al. (2016). Serum-mediated inhibition of enzyme replacement therapy in Fabry disease. The Journal of the American Society of Nephrology, 27, 256\u2013264.","journal-title":"The Journal of the American Society of Nephrology"},{"key":"13_CR80","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1111\/j.1365-2249.2004.02567.x","volume":"137","author":"RD Garman","year":"2004","unstructured":"Garman, R. D., Munroe, K., & Richards, S. M. (2004). Methotrexate reduces antibody responses to recombinant human alpha-galactosidase a therapy in a mouse model of Fabry disease. Clinical and Experimental Immunology, 137, 496\u2013502.","journal-title":"Clinical and Experimental Immunology"},{"key":"13_CR81","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.clim.2017.01.014","volume":"178","author":"Y Sato","year":"2017","unstructured":"Sato, Y., Ida, H., & Ohashi, T. (2017). Anti-BlyS antibody reduces the immune reaction against enzyme and enhances the efficacy of enzyme replacement therapy in Fabry disease model mice. Clinical Immunology, 178, 56\u201363.","journal-title":"Clinical Immunology"},{"key":"13_CR82","doi-asserted-by":"publisher","first-page":"271","DOI":"10.3390\/biom11020271","volume":"11","author":"K Kok","year":"2021","unstructured":"Kok, K., et al. (2021). Fabry disease: Molecular basis, pathophysiology, diagnostics and potential therapeutic directions. Biomolecules, 11, 271.","journal-title":"Biomolecules"},{"key":"13_CR83","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1002\/jimd.12228","volume":"43","author":"SJ van der Veen","year":"2020","unstructured":"van der Veen, S. J., Hollak, C. E. M., van Kuilenburg, A. B. P., & Langeveld, M. (2020). Developments in the treatment of Fabry disease. Journal of Inherited Metabolic Disease, 43, 908\u2013921.","journal-title":"Journal of Inherited Metabolic Disease"},{"key":"13_CR84","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1002\/cpdd.865","volume":"10","author":"MJ Peterschmitt","year":"2021","unstructured":"Peterschmitt, M. J., et al. (2021). Pharmacokinetics, pharmacodynamics, safety, and tolerability of Oral Venglustat in healthy volunteers. Clinical Pharmacology in Drug Development, 10, 86\u201398.","journal-title":"Clinical Pharmacology in Drug Development"},{"key":"13_CR85","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s13023-017-0565-9","volume":"12","author":"N Guerard","year":"2017","unstructured":"Guerard, N., Morand, O., & Dingemanse, J. (2017). Lucerastat, an iminosugar with potential as substrate reduction therapy for glycolipid storage disorders: Safety, tolerability, and pharmacokinetics in healthy subjects. Orphanet Journal of Rare Diseases, 12, 9.","journal-title":"Orphanet Journal of Rare Diseases"},{"key":"13_CR86","doi-asserted-by":"publisher","first-page":"389","DOI":"10.2119\/molmed.2015.00088","volume":"21","author":"KM Ashe","year":"2015","unstructured":"Ashe, K. M., et al. (2015). Efficacy of enzyme and substrate reduction therapy with a novel antagonist of glucosylceramide synthase for Fabry disease. Molecular Medicine, 21, 389\u2013399.","journal-title":"Molecular Medicine"},{"key":"13_CR87","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/s40259-013-0032-7","volume":"27","author":"AP Ruiz de Garibay","year":"2013","unstructured":"Ruiz de Garibay, A. P., Solinis, M. A., & Rodriguez-Gascon, A. (2013). Gene therapy for fabry disease: A review of the literature. BioDrugs, 27, 237\u2013246.","journal-title":"BioDrugs"},{"key":"13_CR88","doi-asserted-by":"publisher","first-page":"7825","DOI":"10.1021\/acsami.0c16871","volume":"13","author":"J Tomsen-Melero","year":"2021","unstructured":"Tomsen-Melero, J., et al. (2021). Impact of chemical composition on the nanostructure and biological activity of alpha-galactosidase-loaded nanovesicles for Fabry disease treatment. ACS Applied Materials & Interfaces, 13, 7825\u20137838.","journal-title":"ACS Applied Materials & Interfaces"},{"key":"13_CR89","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1016\/S0140-6736(08)61522-6","volume":"372","author":"GA Grabowski","year":"2008","unstructured":"Grabowski, G. A. (2008). Phenotype, diagnosis, and treatment of Gaucher\u2019s disease. The Lancet, 372, 1263\u20131271.","journal-title":"The Lancet"},{"key":"13_CR90","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/nchembio850","volume":"3","author":"RL Lieberman","year":"2007","unstructured":"Lieberman, R. L., et al. (2007). Structure of acid beta-glucosidase with pharmacological chaperone provides insight into Gaucher disease. Nature Chemical Biology, 3, 101\u2013107.","journal-title":"Nature Chemical Biology"},{"key":"13_CR91","first-page":"1219","volume":"19","author":"WJ Huang","year":"2015","unstructured":"Huang, W. J., Zhang, X., & Chen, W. W. (2015). Gaucher disease: A lysosomal neurodegenerative disorder. European Review for Medical and Pharmacological Sciences, 19, 1219\u20131226.","journal-title":"European Review for Medical and Pharmacological Sciences"},{"key":"13_CR92","doi-asserted-by":"publisher","first-page":"441","DOI":"10.3390\/ijms18020441","volume":"18","author":"J Stirnemann","year":"2017","unstructured":"Stirnemann, J., et al. (2017). A review of Gaucher disease pathophysiology, clinical presentation and treatments. International Journal of Molecular Sciences, 18, 441.","journal-title":"International Journal of Molecular Sciences"},{"key":"13_CR93","doi-asserted-by":"publisher","first-page":"1972","DOI":"10.1056\/NEJMoa033277","volume":"351","author":"J Aharon-Peretz","year":"2004","unstructured":"Aharon-Peretz, J., Rosenbaum, H., & Gershoni-Baruch, R. (2004). Mutations in the glucocerebrosidase gene and Parkinson\u2019s disease in Ashkenazi Jews. New England Journal of Medicine, 351, 1972\u20131977.","journal-title":"New England Journal of Medicine"},{"key":"13_CR94","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.bcmd.2005.07.005","volume":"35","author":"E Beutler","year":"2005","unstructured":"Beutler, E., Gelbart, T., & Scott, C. R. (2005). Hematologically important mutations: Gaucher disease. Blood Cells, Molecules & Diseases, 35, 355\u2013364.","journal-title":"Blood Cells, Molecules & Diseases"},{"key":"13_CR95","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.ymgme.2021.01.002","volume":"132","author":"EC Daykin","year":"2021","unstructured":"Daykin, E. C., Ryan, E., & Sidransky, E. (2021). Diagnosing neuronopathic Gaucher disease: New considerations and challenges in assigning Gaucher phenotypes. Molecular Genetics and Metabolism, 132, 49\u201358.","journal-title":"Molecular Genetics and Metabolism"},{"key":"13_CR96","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1146\/annurev.bi.60.070191.001353","volume":"60","author":"EF Neufeld","year":"1991","unstructured":"Neufeld, E. F. (1991). Lysosomal storage diseases. Annual Review of Biochemistry, 60, 257\u2013280.","journal-title":"Annual Review of Biochemistry"},{"key":"13_CR97","doi-asserted-by":"publisher","first-page":"2835","DOI":"10.1001\/archinte.160.18.2835","volume":"160","author":"J Charrow","year":"2000","unstructured":"Charrow, J., Andersson, H. C., Kaplan, P., Kolodny, E. H., Mistry, P., Pastores, G., Rosenbloom, B. E., Scott, C. R., Wappner, R. S., Weinreb, N. J., & Zimran, A. (2000). The Gaucher registry: Demographics and disease characteristics of 1698 patients with Gaucher disease. Archives of Internal Medicine, 160, 2835\u20132843.","journal-title":"Archives of Internal Medicine"},{"key":"13_CR98","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1182\/blood-2003-05-1612","volume":"103","author":"RG Boot","year":"2004","unstructured":"Boot, R. G., et al. (2004). Marked elevation of the chemokine CCL18\/PARC in Gaucher disease: A novel surrogate marker for assessing therapeutic intervention. Blood, 103, 33\u201339.","journal-title":"Blood"},{"key":"13_CR99","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1172\/JCI117084","volume":"93","author":"CE Hollak","year":"1994","unstructured":"Hollak, C. E., van Weely, S., van Oers, M. H., & Aerts, J. M. (1994). Marked elevation of plasma chitotriosidase activity. A novel hallmark of Gaucher disease. Journal of Clinical Investigation, 93, 1288\u20131292.","journal-title":"Journal of Clinical Investigation"},{"key":"13_CR100","doi-asserted-by":"publisher","first-page":"e118","DOI":"10.1182\/blood-2011-05-352971","volume":"118","author":"N Dekker","year":"2011","unstructured":"Dekker, N., et al. (2011). Elevated plasma glucosylsphingosine in Gaucher disease: Relation to phenotype, storage cell markers, and therapeutic response. Blood, 118, e118\u2013e127.","journal-title":"Blood"},{"key":"13_CR101","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.bcmd.2012.04.002","volume":"49","author":"A Mekinian","year":"2012","unstructured":"Mekinian, A., et al. (2012). Ferritinemia during type 1 Gaucher disease: Mechanisms and progression under treatment. Blood Cells, Molecules & Diseases, 49, 53\u201357.","journal-title":"Blood Cells, Molecules & Diseases"},{"key":"13_CR102","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1185\/030079906X104623","volume":"22","author":"S Vom Dahl","year":"2006","unstructured":"Vom Dahl, S., et al. (2006). Evidence-based recommendations for monitoring bone disease and the response to enzyme replacement therapy in Gaucher patients. Current Medical Research and Opinion, 22, 1045\u20131064.","journal-title":"Current Medical Research and Opinion"},{"key":"13_CR103","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.ymgme.2004.08.015","volume":"83","author":"E Sidransky","year":"2004","unstructured":"Sidransky, E. (2004). Gaucher disease: Complexity in a \u2018simple\u2019 disorder. Molecular Genetics and Metabolism, 83, 6\u201315.","journal-title":"Molecular Genetics and Metabolism"},{"key":"13_CR104","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/1750-1172-7-77","volume":"7","author":"J Stirnemann","year":"2012","unstructured":"Stirnemann, J., et al. (2012). The French Gaucher\u2019s disease registry: Clinical characteristics, complications and treatment of 562 patients. Orphanet Journal of Rare Diseases, 7, 77.","journal-title":"Orphanet Journal of Rare Diseases"},{"key":"13_CR105","doi-asserted-by":"publisher","first-page":"e0039","DOI":"10.5041\/RMMJ.10173","volume":"5","author":"H Rosenbaum","year":"2014","unstructured":"Rosenbaum, H. (2014). Hemorrhagic aspects of Gaucher disease. Rambam Maimonides Medical Journal, 5, e0039.","journal-title":"Rambam Maimonides Medical Journal"},{"key":"13_CR106","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1002\/jbmr.5650111125","volume":"11","author":"GM Pastores","year":"1996","unstructured":"Pastores, G. M., Wallenstein, S., Desnick, R. J., & Luckey, M. M. (1996). Bone density in type 1 Gaucher disease. Journal of Bone and Mineral Research, 11, 1801\u20131807.","journal-title":"Journal of Bone and Mineral Research"},{"key":"13_CR107","doi-asserted-by":"publisher","first-page":"A2","DOI":"10.1259\/bjr.75.suppl_1.750002","volume":"75","author":"RJ Wenstrup","year":"2002","unstructured":"Wenstrup, R. J., Roca-Espiau, M., Weinreb, N. J., & Bembi, B. (2002). Skeletal aspects of Gaucher disease: A review. The British Journal of Radiology, 75, A2\u2013A12.","journal-title":"The British Journal of Radiology"},{"key":"13_CR108","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/S1096-7192(02)00122-1","volume":"77","author":"PK Mistry","year":"2002","unstructured":"Mistry, P. K., et al. (2002). Pulmonary hypertension in type 1 Gaucher\u2019s disease: Genetic and epigenetic determinants of phenotype and response to therapy. Molecular Genetics and Metabolism, 77, 91\u201398.","journal-title":"Molecular Genetics and Metabolism"},{"key":"13_CR109","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1001\/archpedi.160.6.603","volume":"160","author":"P Kaplan","year":"2006","unstructured":"Kaplan, P., Andersson, H. C., Kacena, K. A., & Yee, J. D. (2006). The clinical and demographic characteristics of nonneuronopathic Gaucher disease in 887 children at diagnosis. Archives of Pediatrics and Adolescent Medicine, 160, 603\u2013608.","journal-title":"Archives of Pediatrics and Adolescent Medicine"},{"key":"13_CR110","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.bcmd.2010.08.012","volume":"46","author":"N Gupta","year":"2011","unstructured":"Gupta, N., Oppenheim, I. M., Kauvar, E. F., Tayebi, N., & Sidransky, E. (2011). Type 2 Gaucher disease: Phenotypic variation and genotypic heterogeneity. Blood Cells, Molecules, and Diseases, 46, 75\u201384.","journal-title":"Blood Cells, Molecules, and Diseases"},{"key":"13_CR111","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.braindev.2005.04.005","volume":"28","author":"C Mignot","year":"2006","unstructured":"Mignot, C., Doummar, D., Maire, I., & De Villemeur, T. B. (2006). & French type 2 Gaucher disease study, G. type 2 Gaucher disease: 15 new cases and review of the literature. Brain Dev, 28, 39\u201348.","journal-title":"Brain Dev"},{"key":"13_CR112","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1002\/ajmg.a.20117","volume":"120A","author":"C Mignot","year":"2003","unstructured":"Mignot, C., et al. (2003). Perinatal-lethal Gaucher disease. American Journal of Medical Genetics. Part A, 120A, 338\u2013344.","journal-title":"American Journal of Medical Genetics. Part A"},{"key":"13_CR113","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3390\/diseases5010010","volume":"5","author":"T Roshan Lal","year":"2017","unstructured":"Roshan Lal, T., & Sidransky, E. (2017). The Spectrum of neurological manifestations associated with Gaucher disease. Diseases, 5, 10.","journal-title":"Diseases"},{"key":"13_CR114","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1080\/17446651.2018.1445524","volume":"13","author":"SE Gary","year":"2018","unstructured":"Gary, S. E., Ryan, E., Steward, A. M., & Sidransky, E. (2018). Recent advances in the diagnosis and management of Gaucher disease. Expert Review of Endocrinology and Metabolism, 13, 107\u2013118.","journal-title":"Expert Review of Endocrinology and Metabolism"},{"key":"13_CR115","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.braindev.2010.02.005","volume":"33","author":"I Kraoua","year":"2011","unstructured":"Kraoua, I., et al. (2011). A French experience of type 3 Gaucher disease: Phenotypic diversity and neurological outcome of 10 patients. Brain Dev, 33, 131\u2013139.","journal-title":"Brain Dev"},{"key":"13_CR116","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1034\/j.1399-0004.2001.590511.x","volume":"59","author":"R George","year":"2001","unstructured":"George, R., McMahon, J., Lytle, B., Clark, B., & Lichtin, A. (2001). Severe valvular and aortic arch calcification in a patient with Gaucher\u2019s disease homozygous for the D409H mutation. Clinical Genetics, 59, 360\u2013363.","journal-title":"Clinical Genetics"},{"key":"13_CR117","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1182\/blood-2011-04-308890","volume":"118","author":"A Zimran","year":"2011","unstructured":"Zimran, A. (2011). How I treat Gaucher disease. Blood, 118, 1463\u20131471.","journal-title":"Blood"},{"key":"13_CR118","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1056\/NEJM199105233242104","volume":"324","author":"NW Barton","year":"1991","unstructured":"Barton, N. W., et al. (1991). Replacement therapy for inherited enzyme deficiency\u2014macrophage-targeted glucocerebrosidase for Gaucher\u2019s disease. The New England Journal of Medicine, 324, 1464\u20131470.","journal-title":"The New England Journal of Medicine"},{"key":"13_CR119","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1002\/ana.21491","volume":"64","author":"R Schiffmann","year":"2008","unstructured":"Schiffmann, R., et al. (2008). Randomized, controlled trial of miglustat in Gaucher\u2019s disease type 3. Annals of Neurology, 64, 514\u2013522.","journal-title":"Annals of Neurology"},{"key":"13_CR120","doi-asserted-by":"publisher","first-page":"2355","DOI":"10.1016\/S0140-6736(14)61841-9","volume":"385","author":"TM Cox","year":"2015","unstructured":"Cox, T. M., et al. (2015). Eliglustat compared with imiglucerase in patients with Gaucher\u2019s disease type 1 stabilised on enzyme replacement therapy: A phase 3, randomised, open-label, non-inferiority trial. The Lancet, 385, 2355\u20132362.","journal-title":"The Lancet"},{"key":"13_CR121","doi-asserted-by":"publisher","first-page":"2337","DOI":"10.1182\/blood-2017-02-769034","volume":"129","author":"NJ Weinreb","year":"2017","unstructured":"Weinreb, N. J. (2017). Encore! Oral therapy for type 1 Gaucher disease. Blood, 129, 2337\u20132338.","journal-title":"Blood"},{"key":"13_CR122","doi-asserted-by":"publisher","first-page":"271","DOI":"10.3389\/fcell.2020.00271","volume":"8","author":"TU Han","year":"2020","unstructured":"Han, T. U., Sam, R., & Sidransky, E. (2020). Small molecule chaperones for the treatment of Gaucher disease and GBA1-associated Parkinson disease. Frontiers in Cell and Development Biology, 8, 271.","journal-title":"Frontiers in Cell and Development Biology"},{"key":"13_CR123","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1038\/s41582-018-0053-4","volume":"14","author":"H Wood","year":"2018","unstructured":"Wood, H. (2018). Fetal gene therapy could be feasible for neuronopathic Gaucher disease. Nature Reviews. Neurology, 14, 507.","journal-title":"Nature Reviews. Neurology"},{"issue":"Suppl 2","key":"13_CR124","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1038\/bmt.2008.275","volume":"42","author":"A Biffi","year":"2008","unstructured":"Biffi, A., Lucchini, G., Rovelli, A., & Sessa, M. (2008). Metachromatic leukodystrophy: An overview of current and prospective treatments. Bone Marrow Transplantation, 42(Suppl 2), S2\u2013S6.","journal-title":"Bone Marrow Transplantation"},{"key":"13_CR125","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1002\/humu.22919","volume":"37","author":"M Cesani","year":"2016","unstructured":"Cesani, M., et al. (2016). Mutation update of ARSA and PSAP genes causing metachromatic leukodystrophy. Human Mutation, 37, 16\u201327.","journal-title":"Human Mutation"},{"key":"13_CR126","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1186\/s13023-019-1220-4","volume":"14","author":"S Beerepoot","year":"2019","unstructured":"Beerepoot, S., et al. (2019). Peripheral neuropathy in metachromatic leukodystrophy: Current status and future perspective. Orphanet Journal of Rare Diseases, 14, 240.","journal-title":"Orphanet Journal of Rare Diseases"},{"key":"13_CR127","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1007\/BF00711364","volume":"17","author":"V Gieselmann","year":"1994","unstructured":"Gieselmann, V., Polten, A., Kreysing, J., & von Figura, K. (1994). Molecular genetics of metachromatic leukodystrophy. Journal of Inherited Metabolic Disease, 17, 500\u2013509.","journal-title":"Journal of Inherited Metabolic Disease"},{"key":"13_CR128","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1042\/EBC20190090","volume":"64","author":"M van Eijk","year":"2020","unstructured":"van Eijk, M., Ferraz, M. J., Boot, R. G., & Aerts, J. (2020). Lyso-glycosphingolipids: Presence and consequences. Essays in Biochemistry, 64, 565\u2013578.","journal-title":"Essays in Biochemistry"},{"key":"13_CR129","volume-title":"The metabolic and molecular basis of inherited disease","author":"K Von Figura","year":"2001","unstructured":"Von Figura, K. (2001). Metachromatic leukodystrophy. In The metabolic and molecular basis of inherited disease. McGraw-Hill."},{"key":"13_CR130","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1023\/A:1005471106088","volume":"21","author":"V Gieselmann","year":"1998","unstructured":"Gieselmann, V., et al. (1998). Metachromatic leukodystrophy: Molecular genetics and an animal model. Journal of Inherited Metabolic Disease, 21, 564\u2013574.","journal-title":"Journal of Inherited Metabolic Disease"},{"key":"13_CR131","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1111\/j.1432-1033.1990.tb19167.x","volume":"191","author":"J Kreysing","year":"1990","unstructured":"Kreysing, J., von Figura, K., & Gieselmann, V. (1990). Structure of the arylsulfatase a gene. European Journal of Biochemistry, 191, 627\u2013631.","journal-title":"European Journal of Biochemistry"},{"key":"13_CR132","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1186\/s13023-019-1113-6","volume":"14","author":"S Elgun","year":"2019","unstructured":"Elgun, S., et al. (2019). Phenotypic variation between siblings with metachromatic Leukodystrophy. Orphanet Journal of Rare Diseases, 14, 136.","journal-title":"Orphanet Journal of Rare Diseases"},{"key":"13_CR133","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/j.ymgme.2005.07.010","volume":"86","author":"A Lugowska","year":"2005","unstructured":"Lugowska, A., et al. (2005). Mutations c.459+1G>a and p.P426L in the ARSA gene: Prevalence in metachromatic leukodystrophy patients from European countries. Molecular Genetics and Metabolism, 86, 353\u2013359.","journal-title":"Molecular Genetics and Metabolism"},{"key":"13_CR134","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1055\/s-0030-1253412","volume":"41","author":"V Gieselmann","year":"2010","unstructured":"Gieselmann, V., & Krageloh-Mann, I. (2010). Metachromatic leukodystrophy\u2014An update. Neuropediatrics, 41, 1\u20136.","journal-title":"Neuropediatrics"},{"key":"13_CR135","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1111\/j.1469-8749.2011.04028.x","volume":"53","author":"C Kehrer","year":"2011","unstructured":"Kehrer, C., Blumenstock, G., Gieselmann, V., Krageloh-Mann, I., & German, L. (2011). The natural course of gross motor deterioration in metachromatic leukodystrophy. Developmental Medicine and Child Neurology, 53, 850\u2013855.","journal-title":"Developmental Medicine and Child Neurology"},{"key":"13_CR136","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s13023-019-1060-2","volume":"14","author":"M Harrington","year":"2019","unstructured":"Harrington, M., et al. (2019). Insights into the natural history of metachromatic leukodystrophy from interviews with caregivers. Orphanet Journal of Rare Diseases, 14, 89.","journal-title":"Orphanet Journal of Rare Diseases"},{"key":"13_CR137","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1007\/s00401-017-1739-1","volume":"134","author":"MS van der Knaap","year":"2017","unstructured":"van der Knaap, M. S., & Bugiani, M. (2017). Leukodystrophies: A proposed classification system based on pathological changes and pathogenetic mechanisms. Acta Neuropathologica, 134, 351\u2013382.","journal-title":"Acta Neuropathologica"},{"key":"13_CR138","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1159\/000112162","volume":"13","author":"N Baumann","year":"1991","unstructured":"Baumann, N., et al. (1991). Adult forms of metachromatic leukodystrophy: Clinical and biochemical approach. Developmental Neuroscience, 13, 211\u2013215.","journal-title":"Developmental Neuroscience"},{"key":"13_CR139","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1001\/archneur.1995.00540280098023","volume":"52","author":"AT Hageman","year":"1995","unstructured":"Hageman, A. T., et al. (1995). Clinical symptoms of adult metachromatic leukodystrophy and arylsulfatase a pseudodeficiency. Archives of Neurology, 52, 408\u2013413.","journal-title":"Archives of Neurology"},{"key":"13_CR140","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1212\/WNL.0000000000002811","volume":"87","author":"DF van Rappard","year":"2016","unstructured":"van Rappard, D. F., et al. (2016). Gallbladder and the risk of polyps and carcinoma in metachromatic leukodystrophy. Neurology, 87, 103\u2013111.","journal-title":"Neurology"},{"key":"13_CR141","first-page":"1738","volume":"18","author":"Y Wang","year":"2019","unstructured":"Wang, Y., et al. (2019). Metachromatic leukodystrophy: Characterization of two (p.Leu433Val, p.Gly449Arg) arylsulfatase a mutations. Experimental and Therapeutic Medicine, 18, 1738\u20131744.","journal-title":"Experimental and Therapeutic Medicine"},{"key":"13_CR142","doi-asserted-by":"publisher","first-page":"7235914","DOI":"10.1155\/2019\/7235914","volume":"2019","author":"T Froukh","year":"2019","unstructured":"Froukh, T. (2019). First record mutations in the genes ASPA and ARSA causing leukodystrophy in Jordan. BioMed Research International, 2019, 7235914.","journal-title":"BioMed Research International"},{"key":"13_CR143","doi-asserted-by":"publisher","first-page":"106448","DOI":"10.1016\/j.clineuro.2020.106448","volume":"201","author":"N Mahdieh","year":"2021","unstructured":"Mahdieh, N., et al. (2021). Novel disease-causing variants in a cohort of Iranian patients with metachromatic leukodystrophy and in silico analysis of their pathogenicity. Clinical Neurology and Neurosurgery, 201, 106448.","journal-title":"Clinical Neurology and Neurosurgery"},{"key":"13_CR144","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1080\/14737175.2020.1699060","volume":"20","author":"MR Ashrafi","year":"2020","unstructured":"Ashrafi, M. R., et al. (2020). An update on clinical, pathological, diagnostic, and therapeutic perspectives of childhood leukodystrophies. Expert Review of Neurotherapeutics, 20, 65\u201384.","journal-title":"Expert Review of Neurotherapeutics"},{"key":"13_CR145","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.jchromb.2019.05.035","volume":"1124","author":"S Pajarola","year":"2019","unstructured":"Pajarola, S., et al. (2019). Measurement of recombinant human arylsulfatase a and leukocyte sulfatase activities by analytical isotachophoresis. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences, 1124, 109\u2013113.","journal-title":"Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences"},{"key":"13_CR146","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/0009-8981(87)90068-4","volume":"164","author":"M Lee-Vaupel","year":"1987","unstructured":"Lee-Vaupel, M., & Conzelmann, E. (1987). A simple chromogenic assay for arylsulfatase A. Clinica Chimica Acta: International Journal of Clinical Chemistry, 164, 171\u2013180.","journal-title":"Clinica Chimica Acta: International Journal of Clinical Chemistry"},{"key":"13_CR147","doi-asserted-by":"publisher","first-page":"6341","DOI":"10.1021\/acs.analchem.9b05274","volume":"92","author":"X Hong","year":"2020","unstructured":"Hong, X., et al. (2020). Leukocyte and dried blood spot arylsulfatase a assay by tandem mass spectrometry. Analytical Chemistry, 92, 6341\u20136348.","journal-title":"Analytical Chemistry"},{"key":"13_CR148","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1194\/jlr.M057232","volume":"56","author":"M Mirzaian","year":"2015","unstructured":"Mirzaian, M., Kramer, G., & Poorthuis, B. J. (2015). Quantification of sulfatides and lysosulfatides in tissues and body fluids by liquid chromatography-tandem mass spectrometry. Journal of Lipid Research, 56, 936\u2013943.","journal-title":"Journal of Lipid Research"},{"key":"13_CR149","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1373\/clinchem.2015.245159","volume":"62","author":"Z Spacil","year":"2016","unstructured":"Spacil, Z., et al. (2016). Sulfatide analysis by mass spectrometry for screening of metachromatic leukodystrophy in dried blood and urine samples. Clinical Chemistry, 62, 279\u2013286.","journal-title":"Clinical Chemistry"},{"key":"13_CR150","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1007\/s002470050672","volume":"29","author":"EN Faerber","year":"1999","unstructured":"Faerber, E. N., Melvin, J., & Smergel, E. M. (1999). MRI appearances of metachromatic leukodystrophy. Pediatric Radiology, 29, 669\u2013672.","journal-title":"Pediatric Radiology"},{"key":"13_CR151","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1136\/jnnp.2005.075762","volume":"77","author":"R Nandhagopal","year":"2006","unstructured":"Nandhagopal, R., & Krishnamoorthy, S. G. (2006). Neurological picture. Tigroid and leopard skin pattern of dysmyelination in metachromatic leucodystrophy. Journal of Neurology, Neurosurgery, and Psychiatry, 77, 344.","journal-title":"Journal of Neurology, Neurosurgery, and Psychiatry"},{"key":"13_CR152","doi-asserted-by":"publisher","first-page":"1896","DOI":"10.1212\/WNL.0b013e3181feb217","volume":"75","author":"C i Dali","year":"2010","unstructured":"i Dali, C., et al. (2010). Brain N-acetylaspartate levels correlate with motor function in metachromatic leukodystrophy. Neurology, 75, 1896\u20131903.","journal-title":"Neurology"},{"key":"13_CR153","doi-asserted-by":"publisher","first-page":"576221","DOI":"10.3389\/fmed.2020.576221","volume":"7","author":"AA Shaimardanova","year":"2020","unstructured":"Shaimardanova, A. A., et al. (2020). Metachromatic leukodystrophy: Diagnosis, modeling, and treatment approaches. Frontiers in Medicine, 7, 576221.","journal-title":"Frontiers in Medicine"},{"key":"13_CR154","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1017\/S031716710004823X","volume":"20","author":"AD Sadovnick","year":"1993","unstructured":"Sadovnick, A. D., et al. (1993). The differential diagnosis of adult onset metachromatic leukodystrophy and early onset familial Alzheimer disease in an Alzheimer clinic population. The Canadian Journal of Neurological Sciences, 20, 312\u2013318.","journal-title":"The Canadian Journal of Neurological Sciences"},{"key":"13_CR155","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1176\/ajp.138.10.1372","volume":"138","author":"H Mahon-Haft","year":"1981","unstructured":"Mahon-Haft, H., Stone, R. K., Johnson, R., & Shah, S. (1981). Biochemical abnormalities of metachromatic leukodystrophy in an adult psychiatric population. The American Journal of Psychiatry, 138, 1372\u20131374.","journal-title":"The American Journal of Psychiatry"},{"key":"13_CR156","first-page":"729","volume":"7","author":"SA Patil","year":"2013","unstructured":"Patil, S. A., & Maegawa, G. H. (2013). Developing therapeutic approaches for metachromatic leukodystrophy. Drug Design, Development and Therapy, 7, 729\u2013745.","journal-title":"Drug Design, Development and Therapy"},{"key":"13_CR157","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/S0092-8674(03)00348-9","volume":"113","author":"MP Cosma","year":"2003","unstructured":"Cosma, M. P., et al. (2003). The multiple sulfatase deficiency gene encodes an essential and limiting factor for the activity of sulfatases. Cell, 113, 445\u2013456.","journal-title":"Cell"},{"key":"13_CR158","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1002\/acn3.50975","volume":"7","author":"NI Wolf","year":"2020","unstructured":"Wolf, N. I., et al. (2020). Metachromatic leukodystrophy and transplantation: Remyelination, no cross-correction. Annals of Clinical Translational Neurology, 7, 169\u2013180.","journal-title":"Annals of Clinical Translational Neurology"},{"key":"13_CR159","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1016\/S0140-6736(16)30374-9","volume":"388","author":"M Sessa","year":"2016","unstructured":"Sessa, M., et al. (2016). Lentiviral haemopoietic stem-cell gene therapy in early-onset metachromatic leukodystrophy: An ad-hoc analysis of a non-randomised, open-label, phase 1\/2 trial. The Lancet, 388, 476\u2013487.","journal-title":"The Lancet"},{"key":"13_CR160","doi-asserted-by":"publisher","first-page":"1233158","DOI":"10.1126\/science.1233158","volume":"341","author":"A Biffi","year":"2013","unstructured":"Biffi, A., et al. (2013). Lentiviral hematopoietic stem cell gene therapy benefits metachromatic leukodystrophy. Science, 341, 1233158.","journal-title":"Science"},{"key":"13_CR161","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1097\/00019052-200106000-00007","volume":"14","author":"J Berger","year":"2001","unstructured":"Berger, J., Moser, H. W., & Forss-Petter, S. (2001). Leukodystrophies: Recent developments in genetics, molecular biology, pathogenesis and treatment. Current Opinion in Neurology, 14, 305\u2013312.","journal-title":"Current Opinion in Neurology"},{"key":"13_CR162","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1016\/j.bbmt.2013.01.010","volume":"19","author":"HR Martin","year":"2013","unstructured":"Martin, H. R., et al. (2013). Neurodevelopmental outcomes of umbilical cord blood transplantation in metachromatic leukodystrophy. Biology of Blood and Marrow Transplantation, 19, 616\u2013624.","journal-title":"Biology of Blood and Marrow Transplantation"},{"key":"13_CR163","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1517\/14712598.5.1.55","volume":"5","author":"U Matzner","year":"2005","unstructured":"Matzner, U., & Gieselmann, V. (2005). Gene therapy of metachromatic leukodystrophy. Expert Opinion on Biological Therapy, 5, 55\u201365.","journal-title":"Expert Opinion on Biological Therapy"},{"key":"13_CR164","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1002\/jnr.23792","volume":"94","author":"JB Rosenberg","year":"2016","unstructured":"Rosenberg, J. B., Kaminsky, S. M., Aubourg, P., Crystal, R. G., & Sondhi, D. (2016). Gene therapy for metachromatic leukodystrophy. Journal of Neuroscience Research, 94, 1169\u20131179.","journal-title":"Journal of Neuroscience Research"},{"key":"13_CR165","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1097\/WCO.0b013e328338313a","volume":"23","author":"W Kohler","year":"2010","unstructured":"Kohler, W. (2010). Leukodystrophies with late disease onset: An update. Current Opinion in Neurology, 23, 234\u2013241.","journal-title":"Current Opinion in Neurology"},{"key":"13_CR166","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1007\/s10545-017-0052-4","volume":"40","author":"R Penati","year":"2017","unstructured":"Penati, R., Fumagalli, F., Calbi, V., Bernardo, M. E., & Aiuti, A. (2017). Gene therapy for lysosomal storage disorders: Recent advances for metachromatic leukodystrophy and mucopolysaccaridosis I. Journal of Inherited Metabolic Disease, 40, 543\u2013554.","journal-title":"Journal of Inherited Metabolic Disease"},{"key":"13_CR167","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.ymgme.2011.10.002","volume":"105","author":"SP Batzios","year":"2012","unstructured":"Batzios, S. P., & Zafeiriou, D. I. (2012). Developing treatment options for metachromatic leukodystrophy. Molecular Genetics and Metabolism, 105, 56\u201363.","journal-title":"Molecular Genetics and Metabolism"},{"key":"13_CR168","doi-asserted-by":"publisher","first-page":"2649","DOI":"10.1093\/brain\/awt232","volume":"136","author":"A Compston","year":"2013","unstructured":"Compston, A. (2013). A new familial infantile form of diffuse brain-sclerosis. Brain, 136, 2649\u20132651.","journal-title":"Brain"},{"key":"13_CR169","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1186\/s13023-020-01489-3","volume":"15","author":"SI Krieg","year":"2020","unstructured":"Krieg, S. I., et al. (2020). Natural history of Krabbe disease\u2014A nationwide study in Germany using clinical and MRI data. Orphanet Journal of Rare Diseases, 15, 243.","journal-title":"Orphanet Journal of Rare Diseases"},{"key":"13_CR170","doi-asserted-by":"publisher","first-page":"830","DOI":"10.3389\/fneur.2020.00830","volume":"11","author":"J Zhong","year":"2020","unstructured":"Zhong, J., et al. (2020). Novel GALC mutations cause adult-onset Krabbe disease with myelopathy in two Chinese families: Case reports and literature review. Frontiers in Neurology, 11, 830.","journal-title":"Frontiers in Neurology"},{"key":"13_CR171","volume-title":"Public summary of opinion on orphan designation","author":"EM Agency","year":"2011","unstructured":"Agency, E. M. Public summary of opinion on orphan designation. (2011)."},{"key":"13_CR172","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1111\/ane.13153","volume":"140","author":"G Pannuzzo","year":"2019","unstructured":"Pannuzzo, G., Graziano, A. C. E., Avola, R., Drago, F., & Cardile, V. (2019). Screening for Krabbe disease: The first 2 years\u2019 experience. Acta Neurologica Scandinavica, 140, 359\u2013365.","journal-title":"Acta Neurologica Scandinavica"},{"key":"13_CR173","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.ymgme.2004.10.004","volume":"84","author":"R Spiegel","year":"2005","unstructured":"Spiegel, R., et al. (2005). A mutation in the saposin a coding region of the prosaposin gene in an infant presenting as Krabbe disease: First report of saposin a deficiency in humans. Molecular Genetics and Metabolism, 84, 160\u2013166.","journal-title":"Molecular Genetics and Metabolism"},{"key":"13_CR174","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/8904_2018_114","volume":"44","author":"M Kose","year":"2019","unstructured":"Kose, M., et al. (2019). The second case of Saposin a deficiency and altered autophagy. JIMD Reports, 44, 43\u201354.","journal-title":"JIMD Reports"},{"key":"13_CR175","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1080\/00207454.2020.1731504","volume":"130","author":"X Meng","year":"2020","unstructured":"Meng, X., et al. (2020). A new compound heterozygous mutation in adult-onset Krabbe disease. The International Journal of Neuroscience, 130, 1267\u20131271.","journal-title":"The International Journal of Neuroscience"},{"key":"13_CR176","doi-asserted-by":"publisher","first-page":"346","DOI":"10.5114\/fn.2012.32364","volume":"50","author":"K Szyma\u0144ska","year":"2012","unstructured":"Szyma\u0144ska, K., et al. (2012). Diagnostic difficulties in Krabbe disease: A report of two cases and review of literature. Folia Neuropathologica, 50, 346\u2013356.","journal-title":"Folia Neuropathologica"},{"key":"13_CR177","doi-asserted-by":"publisher","first-page":"2208","DOI":"10.1038\/s41436-019-0480-7","volume":"21","author":"S Komatsuzaki","year":"2019","unstructured":"Komatsuzaki, S., et al. (2019). Clinical characteristics of 248 patients with Krabbe disease: Quantitative natural history modeling based on published cases. Genetics in Medicine, 21, 2208\u20132215.","journal-title":"Genetics in Medicine"},{"key":"13_CR178","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.pediatrneurol.2008.11.010","volume":"40","author":"PK Duffner","year":"2009","unstructured":"Duffner, P. K., et al. (2009). Newborn screening for Krabbe disease: The New York state model. Pediatric Neurology, 40, 245\u2013252.; discussion 253-245.","journal-title":"Pediatric Neurology"},{"key":"13_CR179","doi-asserted-by":"publisher","first-page":"e647","DOI":"10.1212\/WNL.0000000000007943","volume":"93","author":"L Cousyn","year":"2019","unstructured":"Cousyn, L., et al. (2019). Brain MRI features and scoring of leukodystrophy in adult-onset Krabbe disease. Neurology, 93, e647\u2013e652.","journal-title":"Neurology"},{"key":"13_CR180","doi-asserted-by":"publisher","first-page":"29","DOI":"10.3390\/ijns6020029","volume":"6","author":"Z Herbst","year":"2020","unstructured":"Herbst, Z., et al. (2020). Achieving congruence among reference laboratories for absolute abundance measurement of analytes for rare diseases: Psychosine for diagnosis and prognosis of Krabbe disease. International Journal of Neonatal Screening, 6, 29.","journal-title":"International Journal of Neonatal Screening"},{"key":"13_CR181","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.gene.2014.09.046","volume":"555","author":"AC Graziano","year":"2015","unstructured":"Graziano, A. C., & Cardile, V. (2015). History, genetic, and recent advances on Krabbe disease. Gene, 555, 2\u201313.","journal-title":"Gene"},{"key":"13_CR182","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s13023-018-0766-x","volume":"13","author":"JM Kwon","year":"2018","unstructured":"Kwon, J. M., et al. (2018). Consensus guidelines for newborn screening, diagnosis and treatment of infantile Krabbe disease. Orphanet Journal of Rare Diseases, 13, 30.","journal-title":"Orphanet Journal of Rare Diseases"},{"key":"13_CR183","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1111\/dmcn.14258","volume":"61","author":"P Ehmann","year":"2019","unstructured":"Ehmann, P., & Lantos, J. D. (2019). Ethical issues with testing and treatment for Krabbe disease. Developmental Medicine and Child Neurology, 61, 1358\u20131361.","journal-title":"Developmental Medicine and Child Neurology"},{"key":"13_CR184","first-page":"e4767","volume":"11","author":"B Pati\u00f1o-Escobar","year":"2019","unstructured":"Pati\u00f1o-Escobar, B., Solano, M. H., Zarabanda, L., Casas, C. P., & Castro, C. (2019). Niemann-pick disease: An approach for diagnosis in adulthood. Cureus, 11, e4767.","journal-title":"Cureus"},{"key":"13_CR185","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.beem.2014.10.002","volume":"29","author":"EH Schuchman","year":"2015","unstructured":"Schuchman, E. H., & Wasserstein, M. P. (2015). Types A and B Niemann-Pick disease. Best Practice & Research. Clinical Endocrinology & Metabolism, 29, 237\u2013247.","journal-title":"Best Practice & Research. Clinical Endocrinology & Metabolism"},{"key":"13_CR186","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1093\/ajcn\/9.1.63","volume":"9","author":"AC Crocker","year":"1961","unstructured":"Crocker, A. C., & Mays, V. B. (1961). Sphingomyelin synthesis in Niemann-Pick disease. The American Journal of Clinical Nutrition, 9, 63\u201367.","journal-title":"The American Journal of Clinical Nutrition"},{"key":"13_CR187","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1016\/j.cellsig.2009.01.026","volume":"21","author":"RW Jenkins","year":"2009","unstructured":"Jenkins, R. W., Canals, D., & Hannun, Y. A. (2009). Roles and regulation of secretory and lysosomal acid sphingomyelinase. Cellular Signalling, 21, 836\u2013846.","journal-title":"Cellular Signalling"},{"key":"13_CR188","doi-asserted-by":"publisher","first-page":"101461","DOI":"10.1016\/j.scr.2019.101461","volume":"38","author":"A Baskfield","year":"2019","unstructured":"Baskfield, A., et al. (2019). An induced pluripotent stem cell line (TRNDi009-C) from a Niemann-Pick disease type a patient carrying a heterozygous p.L302P (c.905 T>C) mutation in the SMPD1 gene. Stem Cell Research, 38, 101461.","journal-title":"Stem Cell Research"},{"key":"13_CR189","volume-title":"GeneReviews\u00ae [Internet]","author":"MP Wasserstein","year":"1993","unstructured":"Wasserstein, M. P., & Schuchman, E. H. (1993). In M. P. Adam, H. H. Ardinger, R. A. Pagon, et al. (Eds.), GeneReviews\u00ae [Internet]. University of Washington, Seattle."},{"key":"13_CR190","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1111\/cge.12076","volume":"84","author":"P Irun","year":"2013","unstructured":"Irun, P., et al. (2013). Identification of seven novel SMPD1 mutations causing Niemann-Pick disease types a and B. Clinical Genetics, 84, 356\u2013361.","journal-title":"Clinical Genetics"},{"key":"13_CR191","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1002\/lt.25457","volume":"25","author":"Y Liu","year":"2019","unstructured":"Liu, Y., et al. (2019). The effects of liver transplantation in children with Niemann-Pick disease type B. Liver Transplantation, 25, 1233\u20131240.","journal-title":"Liver Transplantation"},{"key":"13_CR192","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.ymgme.2016.12.008","volume":"120","author":"EH Schuchman","year":"2017","unstructured":"Schuchman, E. H., & Desnick, R. J. (2017). Types a and B Niemann-Pick disease. Molecular Genetics and Metabolism, 120, 27\u201333.","journal-title":"Molecular Genetics and Metabolism"},{"key":"13_CR193","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1126\/scitranslmed.aat3738","volume":"11","author":"L Samaranch","year":"2019","unstructured":"Samaranch, L., et al. (2019). Adeno-associated viral vector serotype 9-based gene therapy for Niemann-Pick disease type A. Science Translational Medicine, 11, 1\u201315.","journal-title":"Science Translational Medicine"},{"key":"13_CR194","first-page":"499","volume":"84","author":"S Farber","year":"1952","unstructured":"Farber, S. (1952). A lipid metabolic disorder: Disseminated lipogranulomatosis; a syndrome with similarity to, and important difference from, Niemann-Pick and hand-Sch\u00fcller-Christian disease. American Journal of Diseases of Children, 84, 499\u2013500.","journal-title":"American Journal of Diseases of Children"},{"key":"13_CR195","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.ajhg.2012.05.001","volume":"91","author":"J Zhou","year":"2012","unstructured":"Zhou, J., et al. (2012). Spinal muscular atrophy associated with progressive myoclonic epilepsy is caused by mutations in ASAH1. American Journal of Human Genetics, 91, 5\u201314.","journal-title":"American Journal of Human Genetics"},{"key":"13_CR196","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1006\/geno.1999.5940","volume":"62","author":"CM Li","year":"1999","unstructured":"Li, C. M., et al. (1999). The human acid ceramidase gene (ASAH): Structure, chromosomal location, mutation analysis, and expression. Genomics, 62, 223\u2013231.","journal-title":"Genomics"},{"key":"13_CR197","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1186\/s13023-018-0845-z","volume":"13","author":"FPS Yu","year":"2018","unstructured":"Yu, F. P. S., Amintas, S., Levade, T., & Medin, J. A. (2018). Acid ceramidase deficiency: Farber disease and SMA-PME. Orphanet Journal of Rare Diseases, 13, 121.","journal-title":"Orphanet Journal of Rare Diseases"},{"key":"13_CR198","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/S0022-3476(76)80927-4","volume":"89","author":"JT Dulaney","year":"1976","unstructured":"Dulaney, J. T., Milunsky, A., Sidbury, J. B., Hobolth, N., & Moser, H. W. (1976). Diagnosis of lipogranulomatosis (Farber disease) by use of cultured fibroblasts. The Journal of Pediatrics, 89, 59\u201361.","journal-title":"The Journal of Pediatrics"},{"key":"13_CR199","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1111\/j.1399-0004.1989.tb03364.x","volume":"36","author":"Y Ben-Yoseph","year":"1989","unstructured":"Ben-Yoseph, Y., Gagn\u00e9, R., Parvathy, M. R., Mitchell, D. A., & Momoi, T. (1989). Leukocyte and plasma N-laurylsphingosine deacylase (ceramidase) in Farber disease. Clinical Genetics, 36, 38\u201342.","journal-title":"Clinical Genetics"},{"key":"13_CR200","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1016\/S0140-6736(79)92562-5","volume":"2","author":"AH Fensom","year":"1979","unstructured":"Fensom, A. H., et al. (1979). Prenatal diagnosis of Farber\u2019s disease. Lancet (London, England), 2, 990\u2013992.","journal-title":"Lancet (London, England)"},{"key":"13_CR201","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/0009-8981(95)06173-8","volume":"245","author":"M Chatelut","year":"1996","unstructured":"Chatelut, M., et al. (1996). A simple method for screening for Farber disease on cultured skin fibroblasts. Clinica Chimica Acta; International Journal of Clinical Chemistry, 245, 61\u201371.","journal-title":"Clinica Chimica Acta; International Journal of Clinical Chemistry"},{"key":"13_CR202","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1016\/0002-9343(69)90202-2","volume":"47","author":"HW Moser","year":"1969","unstructured":"Moser, H. W., Prensky, A. L., Wolfe, H. J., & Rosman, N. P. (1969). Farber\u2019s lipogranulomatosis. Report of a case and demonstration of an excess of free ceramide and ganglioside. The American Journal of Medicine, 47, 869\u2013890.","journal-title":"The American Journal of Medicine"},{"key":"13_CR203","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1093\/clinchem\/21.6.725","volume":"21","author":"M Iwamori","year":"1975","unstructured":"Iwamori, M., & Moser, H. W. (1975). Above-normal urinary excretion of urinary ceramides in Farber\u2019s disease, and characterization of their components by high-performance liquid chromatography. Clinical Chemistry, 21, 725\u2013729.","journal-title":"Clinical Chemistry"},{"key":"13_CR204","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1016\/j.bbadis.2016.11.031","volume":"1863","author":"S Dworski","year":"2017","unstructured":"Dworski, S., et al. (2017). Acid ceramidase deficiency is characterized by a unique plasma cytokine and ceramide profile that is altered by therapy. Biochimica et Biophysica Acta: Molecular Basis of Disease, 1863, 386\u2013394.","journal-title":"Biochimica et Biophysica Acta: Molecular Basis of Disease"},{"key":"13_CR205","doi-asserted-by":"publisher","first-page":"6149","DOI":"10.1038\/s41598-017-06604-2","volume":"7","author":"C Cozma","year":"2017","unstructured":"Cozma, C., et al. (2017). C26-ceramide as highly sensitive biomarker for the diagnosis of Farber disease. Scientific Reports, 7, 6149.","journal-title":"Scientific Reports"},{"key":"13_CR206","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/BF00694628","volume":"266","author":"C Schmoeckel","year":"1979","unstructured":"Schmoeckel, C., & Hohlfed, M. (1979). A specific ultrastructural marker for disseminated lipogranulomatosis (Faber). Archives of Dermatological Research, 266, 187\u2013196.","journal-title":"Archives of Dermatological Research"},{"key":"13_CR207","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1007\/BF01600282","volume":"420","author":"L Zappatini-Tommasi","year":"1992","unstructured":"Zappatini-Tommasi, L., Dumontel, C., Guibaud, P., & Girod, C. (1992). Farber disease: An ultrastructural study. Report of a case and review of the literature. Virchows Archiv A Pathological Anatomy and Histopathology, 420, 281\u2013290.","journal-title":"Virchows Archiv A Pathological Anatomy and Histopathology"},{"key":"13_CR208","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1001\/archopht.1985.01050010077025","volume":"103","author":"MA Zarbin","year":"1985","unstructured":"Zarbin, M. A., Green, W. R., Moser, H. W., & Morton, S. J. (1985). Farber\u2019s disease. Light and electron microscopic study of the eye. Archives of Ophthalmology, 103, 73\u201380.","journal-title":"Archives of Ophthalmology"},{"key":"13_CR209","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1002\/emmm.201202301","volume":"5","author":"AM Alayoubi","year":"2013","unstructured":"Alayoubi, A. M., et al. (2013). Systemic ceramide accumulation leads to severe and varied pathological consequences. EMBO Molecular Medicine, 5, 827\u2013842.","journal-title":"EMBO Molecular Medicine"},{"key":"13_CR210","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1007\/BF00441558","volume":"148","author":"C Fusch","year":"1989","unstructured":"Fusch, C., et al. (1989). A case of combined Farber and Sandhoff disease. European Journal of Pediatrics, 148, 558\u2013562.","journal-title":"European Journal of Pediatrics"},{"key":"13_CR211","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/BF02024331","volume":"149","author":"K Harzer","year":"1989","unstructured":"Harzer, K., et al. (1989). Sphingolipid activator protein deficiency in a 16-week-old atypical Gaucher disease patient and his fetal sibling: Biochemical signs of combined sphingolipidoses. European Journal of Pediatrics, 149, 31\u201339.","journal-title":"European Journal of Pediatrics"},{"key":"13_CR212","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1093\/hmg\/10.9.927","volume":"10","author":"H Hulkov\u00e1","year":"2001","unstructured":"Hulkov\u00e1, H., et al. (2001). A novel mutation in the coding region of the prosaposin gene leads to a complete deficiency of prosaposin and saposins, and is associated with a complex sphingolipidosis dominated by lactosylceramide accumulation. Human Molecular Genetics, 10, 927\u2013940.","journal-title":"Human Molecular Genetics"},{"key":"13_CR213","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1007\/s10545-012-9573-z","volume":"36","author":"MM Kostik","year":"2013","unstructured":"Kostik, M. M., et al. (2013). Farber lipogranulomatosis with predominant joint involvement mimicking juvenile idiopathic arthritis. Journal of Inherited Metabolic Disease, 36, 1079\u20131080.","journal-title":"Journal of Inherited Metabolic Disease"},{"key":"13_CR214","first-page":"137","volume-title":"Correction of certain genetic diseases by transplantation","author":"G Souillet","year":"1989","unstructured":"Souillet, G., Guiband, P., Fensom, A., Maire, I., & Zabot, M. (1989). Outcome of displacement bone marrow transplantation in Farber\u2019s disease: A report of a case. In Correction of certain genetic diseases by transplantation (pp. 137\u2013141). COGENT."},{"key":"13_CR215","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1002\/jimd.12043","volume":"42","author":"K Ehlert","year":"2019","unstructured":"Ehlert, K., et al. (2019). Allogeneic hematopoietic cell transplantation in Farber disease. Journal of Inherited Metabolic Disease, 42, 286\u2013294.","journal-title":"Journal of Inherited Metabolic Disease"},{"key":"13_CR216","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/S0002-9343(02)01150-6","volume":"113","author":"NJ Weinreb","year":"2002","unstructured":"Weinreb, N. J., et al. (2002). Effectiveness of enzyme replacement therapy in 1028 patients with type 1 Gaucher disease after 2 to 5 years of treatment: A report from the Gaucher registry. The American Journal of Medicine, 113, 112\u2013119.","journal-title":"The American Journal of Medicine"},{"key":"13_CR217","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.bbacli.2017.02.001","volume":"7","author":"X He","year":"2017","unstructured":"He, X., et al. (2017). Enzyme replacement therapy for Farber disease: Proof-of-concept studies in cells and mice. BBA Clinical, 7, 85\u201396.","journal-title":"BBA Clinical"}],"container-title":["Advances in Experimental Medicine and Biology","Sphingolipid Metabolism and Metabolic Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-981-19-0394-6_13","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,20]],"date-time":"2023-11-20T23:54:41Z","timestamp":1700524481000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-981-19-0394-6_13"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022]]},"ISBN":["9789811903939","9789811903946"],"references-count":217,"URL":"https:\/\/doi.org\/10.1007\/978-981-19-0394-6_13","relation":{},"ISSN":["0065-2598","2214-8019"],"issn-type":[{"value":"0065-2598","type":"print"},{"value":"2214-8019","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022]]},"assertion":[{"value":"3 May 2022","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}